Las tabletas de Rybelsus (semaglutide) son un medicamento recetado que se usa en adultos con diabetes mellitus tipo 2 para disminuir los niveles de azúcar en la sangre. Rybelsus se puede recetar cuando se han probado otros medicamentos para la diabetes sin éxito y se debe usar junto con dieta y ejercicio. Las tabletas de Rybelsus funcionan para reducir los niveles de azúcar en la sangre (glucosa) al aumentar la cantidad de insulina que se libera y disminuir la secreción de glucagón. Este medicamento también puede retardar el vaciado gástrico después de comer.

Empaquetado Precio Per comprimido Ahorro Order
3mg × 30 tablet € 476.50 € 15.88 Per comprimido
  • Free AirMail shipping
3mg × 60 tablet € 896.98 € 14.95 Per comprimido € 56.02
  • Free AirMail shipping
3mg × 90 tablet € 1261.39 € 14.02 Per comprimido € 168.10
  • Free AirMail shipping
Empaquetado Precio Per comprimido Ahorro Order
7mg × 30 tablet € 532.56 € 17.75 Per comprimido
  • Free AirMail shipping
7mg × 60 tablet € 1037.14 € 17.29 Per comprimido € 27.99
  • Free AirMail shipping
7mg × 90 tablet € 1513.68 € 16.82 Per comprimido € 84.00
  • Free AirMail shipping
Empaquetado Precio Per comprimido Ahorro Order
14mg × 30 tablet € 630.67 € 21.02 Per comprimido
  • Free AirMail shipping
14mg × 60 tablet € 1233.36 € 20.56 Per comprimido € 27.99
  • Free AirMail shipping
14mg × 90 tablet € 1808.02 € 20.09 Per comprimido € 84.00
  • Free AirMail shipping

Rybelsus® tablets

What is Rybelsus?

Rybelsus tablets (semaglutide) is a prescription medicine used in adults with type 2 diabetes mellitus to decrease blood sugar levels. Rybelsus can be prescribed when other diabetes medicines have been tried without success, and should be used together with diet and exercise.

Rybelsus tablets work to lower blood sugar (glucose) levels by increasing how much insulin is released and decreasing glucagon secretion. This medicine also may slow gastric emptying after eating. Rybelsus is from the class of medicines called GLP-1 receptor agonists.
Rybelsus is not for treating type 1 diabetes.
Rybelsus was first approved by the FDA on September 20, 2019.

Warnings

You should not use Rybelsus if you have multiple endocrine neoplasia type 2 (tumors in your glands), a personal or family history of medullary thyroid cancer, insulin-dependent diabetes, or diabetic ketoacidosis.
Call your doctor at once if you have signs of a thyroid tumor, such as swelling or a lump in your neck, trouble swallowing, a hoarse voice, or shortness of breath.

Al estar en nuestro sitio web, Usted automáticamente acepta el almacenamiento y procesamiento de sus datos personales, según nuestra Política de privacidad.